With communities and economies everywhere affected by the growing COVID-19 pandemic, Danaher will donate to four organizations focused on COVID-19 relief efforts.
The test is the first rapid point-of-care solution to receive EUA FDA approval and is designed to operate on any of Cepheid's more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
Our Global Response Team is committed to protecting associate safety and well-being by actively monitoring, preparing and managing our global COVID-19 business response 24/7 based on direction from international health organizations, local governments and our own safety protocols.